Multivariate analyses of outcomes according to best response in the intent-to-treat population, by IMWG criteria
| . | Hazard ratios (95% CI) . | ||
|---|---|---|---|
| Versus VGPR . | Versus PR . | Versus < PR . | |
| TTP | |||
| Patients achieving CR | 0.45 (0.24-0.88), P = .019 | 0.50 (0.29-0.87), P = .013 | 0.29 (0.17-0.52), P < .0001 |
| Patients achieving VGPR | — | 1.11 (0.63-1.96), P = .73 | 0.64 (0.36-1.15), P = .14 |
| Patients achieving PR | — | — | 0.58 (0.42-0.81), P = .001 |
| Patients achieving CR + VGPR | — | 0.60 (0.38-0.94), P = .025 | 0.37 (0.23-0.59), P < .0001 |
| TNT | |||
| Patients achieving CR | 0.52 (0.34-0.81), P = .004 | 0.58 (0.41-0.81), P = .001 | 0.40 (0.28-0.57), P = .0001 |
| Patients achieving VGPR | — | 1.10 (0.74-1.65), P = .64 | 0.76 (0.50-1.16), P = .20 |
| Patients achieving PR | — | — | 0.69 (0.55-0.88), P = .002 |
| Patients achieving CR + VGPR | — | 0.65 (0.49-0.88), P = .005 | 0.47 (0.34-0.64), P < .0001 |
| TFI | |||
| Patients achieving CR | 0.45 (0.28-0.72), P = .0008 | 0.50 (0.36-0.71), P = .0001 | 0.30 (0.21-0.43), P < .0001 |
| Patients achieving VGPR | — | 1.12 (0.73-1.72), P = .61 | 0.67 (0.44-1.04), P = .072 |
| Patients achieving PR | — | — | 0.60 (0.48-0.76), P < .0001 |
| Patients achieving CR + VGPR | — | 0.63 (0.46-0.85), P = .002 | 0.38 (0.28-0.52), P < .0001 |
| OS | |||
| Patients achieving CR | 0.96 (0.53-1.75), P = .90 | 0.89 (0.58-1.36), P = .58 | 0.46 (0.31-0.67), P = .0001 |
| Patients achieving VGPR | — | 0.92 (0.52-1.62), P = .78 | 0.47 (0.27-0.82), P = .008 |
| Patients achieving PR | — | — | 0.52 (0.38-0.70), P < .0001 |
| Patients achieving CR + VGPR | — | 0.88 (0.59-1.32), P = .54 | 0.51 (0.34-0.75), P = .0007 |
| . | Hazard ratios (95% CI) . | ||
|---|---|---|---|
| Versus VGPR . | Versus PR . | Versus < PR . | |
| TTP | |||
| Patients achieving CR | 0.45 (0.24-0.88), P = .019 | 0.50 (0.29-0.87), P = .013 | 0.29 (0.17-0.52), P < .0001 |
| Patients achieving VGPR | — | 1.11 (0.63-1.96), P = .73 | 0.64 (0.36-1.15), P = .14 |
| Patients achieving PR | — | — | 0.58 (0.42-0.81), P = .001 |
| Patients achieving CR + VGPR | — | 0.60 (0.38-0.94), P = .025 | 0.37 (0.23-0.59), P < .0001 |
| TNT | |||
| Patients achieving CR | 0.52 (0.34-0.81), P = .004 | 0.58 (0.41-0.81), P = .001 | 0.40 (0.28-0.57), P = .0001 |
| Patients achieving VGPR | — | 1.10 (0.74-1.65), P = .64 | 0.76 (0.50-1.16), P = .20 |
| Patients achieving PR | — | — | 0.69 (0.55-0.88), P = .002 |
| Patients achieving CR + VGPR | — | 0.65 (0.49-0.88), P = .005 | 0.47 (0.34-0.64), P < .0001 |
| TFI | |||
| Patients achieving CR | 0.45 (0.28-0.72), P = .0008 | 0.50 (0.36-0.71), P = .0001 | 0.30 (0.21-0.43), P < .0001 |
| Patients achieving VGPR | — | 1.12 (0.73-1.72), P = .61 | 0.67 (0.44-1.04), P = .072 |
| Patients achieving PR | — | — | 0.60 (0.48-0.76), P < .0001 |
| Patients achieving CR + VGPR | — | 0.63 (0.46-0.85), P = .002 | 0.38 (0.28-0.52), P < .0001 |
| OS | |||
| Patients achieving CR | 0.96 (0.53-1.75), P = .90 | 0.89 (0.58-1.36), P = .58 | 0.46 (0.31-0.67), P = .0001 |
| Patients achieving VGPR | — | 0.92 (0.52-1.62), P = .78 | 0.47 (0.27-0.82), P = .008 |
| Patients achieving PR | — | — | 0.52 (0.38-0.70), P < .0001 |
| Patients achieving CR + VGPR | — | 0.88 (0.59-1.32), P = .54 | 0.51 (0.34-0.75), P = .0007 |
CI indicates confidence interval; CR, complete response; IMWG, International Myeloma Working Group; OS, overall survival; PR, partial response; TFI, treatment-free interval; TNT, time to next therapy; TTP, time to progression; VGPR, very good partial response; and —, not applicable.